With a low implementation rate (<25%) and considering the suboptimal performance of ultrasound and AFP for early detection of HCC (63% sensitivity for early stages), there is an urgent need to develop new tools for HCC surveillance and to increase the adherence to the screening programs [37,40,41]. This evidence concerns the gene AFP and hepatocellular carcinoma.